<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737397</url>
  </required_header>
  <id_info>
    <org_study_id>JMI-001-001</org_study_id>
    <nct_id>NCT02737397</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Combination Product for the Prevention of Veisalgia</brief_title>
  <official_title>A Double-blind Placebo-controlled 4-Way Crossover Study to Evaluate the Efficacy of JMI-001 (an Over-the-counter Pain Medicine and an Antihistamine) in the Prophylaxis of Veisalgia in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JMI Capital Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JMI Capital Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of a combination product
      for the prevention of veisalgia. Common symptoms of veisalgia following the moderate
      consumption of alcohol includes headache, fatigue, and thirst. It is the investigators
      hypothesis that a combination of two drugs can alleviate or significantly reduce these
      symptoms when taken before the start of moderate alcohol consumption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some people who consume alcohol in moderation experience veisalgia. These symptoms include a
      long list of adverse effects that include headache, fatigue and thirst. The mechanism by
      which these effects occur has not been fully elucidated. Although, it has been documented
      that alcohol causes the release of a large number of substances into the blood stream that
      cause a number of physiologic changes.

      A 4-arm study will help to determine the effect each agent contributes to decreasing the
      alcohol induces physiologic changes and the effect when the two agents are delivered
      concurrently.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Side Effect Prevention Using the Acute Hangover Scale</measure>
    <time_frame>24 hours</time_frame>
    <description>Efficacy of pain medicine + antihistamine in reducing (as compared to placebo) symptoms associated with Veisalgia. The Acute Hangover Scale (AHS) will be used to evaluate side effects on the following morning post alcohol consumption. The scale includes 9 symptom assessments each ranging from 0-10. The total score can range from 0-90. (0= no symptoms, 10 = worst symptom ever).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Veisalgia</condition>
  <arm_group>
    <arm_group_label>pain medicine and antihistamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JMI-001 (SJP-304 and SJP-223)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pain medicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SJP-304 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antihistamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SJP-223 and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JMI-001 (SJP-304 and SJP-223)</intervention_name>
    <arm_group_label>pain medicine and antihistamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SJP-304</intervention_name>
    <arm_group_label>pain medicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SJP-223</intervention_name>
    <arm_group_label>antihistamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>antihistamine</arm_group_label>
    <arm_group_label>pain medicine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, nonsmoking men or women between 25 and 65 years inclusive

          -  Good general health as determined by a thorough medical history and physical
             examination including vital signs

          -  Subject is a self-reported moderate drinker of alcohol. Moderate drinking can be
             approximated with a blood alcohol concentration (BAC) of 0.04 - 0.11%. The 0.04% -
             0.11% BAC correlates approximately with a 120-160 pound female drinking 2 to 5 drinks
             in 2 to 3 hours, respectively, and a 160-200 pound male drinking 3 to 7 drinks in 2 to
             3 hours, respectively.

          -  Subject has had a moderate to heavy drinking episode in the past 90 days that produced
             hangover symptoms

          -  Subject is knowledgeable of the amount of alcohol he/she needs to consume over a 2 to
             3 hour period of time to produce hangover symptoms

          -  Body mass index between 19 and 32 kg/m2, inclusive

          -  Report a regular, habitual bedtime between 21:30 and 24:00

          -  Females of childbearing potential must be using an acceptable method of contraception
             (see Section 8.5) or have been surgically sterilized and have a negative urine
             pregnancy test at screening and upon admission for each treatment visit

          -  Subject is capable of understanding the requirements of the study and to give written
             informed consent

          -  Subject is able to follow study instructions and is willing to complete all study
             visits and procedures

        Exclusion Criteria:

          -  Acute illness within 14 days prior to screening visit

          -  Allergic reaction or upper respiratory tract infection within 7 days of screening
             visit

          -  Vaccination administration within 7 days of screening visit

          -  Clinically significant, unstable medical illness

          -  Evidence or history of clinically significant allergic (except for untreated,
             asymptomatic, seasonal allergies at time of dosing), hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic or neurological disease

          -  History of cancer or diabetes

          -  Subject has a previous or current Substance-Related Disorder as defined by DSM-5

          -  Self-report of a usual consumption of more than 14 units of alcohol per week. One unit
             of alcohol is equivalent to 12 ounces of beer, 4 ounces of wine, or

             1 ounce of liquor

          -  Self-report of recent (within one month) or current use of smoked or chewed tobacco
             products, or use of nicotine (e.g., nicotine gum or patch)

          -  Positive alcohol breathalyzer test at screening or at check-in for any treatment visit

          -  Positive urine drug screen at screening or at check-in for any treatment visit

          -  A supine blood pressure &gt; 140/90 mm/Hg at screening

          -  Heart rate &gt; 100 beats per minute at screening

          -  Subjects who are unwilling to forgo caffeine consumption with or following dinner on
             each treatment night or who are unwilling to comply with study restrictions for
             prohibited medications/ foods throughout study participation.

          -  Clinically significant psychiatric illness, including chronic psychiatric illness or
             the history or presence of any Axis I condition

          -  Any clinically significant abnormal finding on physical examination or vital signs

          -  Positive pregnancy test at screening or at check-in for any treatment visit

          -  Subject has previously experienced an allergic reaction or adverse event associated
             with aspirin, NSAIDs, or antihistamine usage, including a reaction of not effective

          -  Subject is taking any prescription or over-the-counter oral pain medication(s) for any
             reason

          -  Subject is taking prescription or over-the-counter antihistamine(s)

          -  Women who are pregnant or breastfeeding

          -  Any medical condition or any condition or situation that in the investigator's opinion
             may put the subject at significant risk, confound the study results, or interfere
             significantly with the subject's participation in the study

          -  Concurrent participation in an investigational drug or device study, or use of any
             investigational drug within 30 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy L Shenouda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, Inc.</affiliation>
  </overall_official>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <results_first_submitted>August 5, 2017</results_first_submitted>
  <results_first_submitted_qc>July 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2018</results_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a 4 way cross-over study where 13 individuals received a single dose of an agent in a randomized sequence. All participants were intended to receive all four interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>JMI-001 (SJP-304 and SJP-223), single dose
SJP-304 + placebo
SJP-223 + placebo
placebo + placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>JMI-001</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SJP-304</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SJP-223</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants were randomized to receive 4 sequences of drug therapy including placebo.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Veisalgia with pre-determined consumption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Side Effect Prevention Using the Acute Hangover Scale</title>
        <description>Efficacy of pain medicine + antihistamine in reducing (as compared to placebo) symptoms associated with Veisalgia. The Acute Hangover Scale (AHS) will be used to evaluate side effects on the following morning post alcohol consumption. The scale includes 9 symptom assessments each ranging from 0-10. The total score can range from 0-90. (0= no symptoms, 10 = worst symptom ever).</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pain Medicine and Antihistamine</title>
            <description>JMI-001 (SJP-304 and SJP-223)
JMI-001 (SJP-304 and SJP-223)</description>
          </group>
          <group group_id="O2">
            <title>Pain Medicine</title>
            <description>SJP-304 and placebo
SJP-304
placebo</description>
          </group>
          <group group_id="O3">
            <title>Antihistamine</title>
            <description>SJP-223 and placebo
SJP-223
placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo + placebo, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Side Effect Prevention Using the Acute Hangover Scale</title>
          <description>Efficacy of pain medicine + antihistamine in reducing (as compared to placebo) symptoms associated with Veisalgia. The Acute Hangover Scale (AHS) will be used to evaluate side effects on the following morning post alcohol consumption. The scale includes 9 symptom assessments each ranging from 0-10. The total score can range from 0-90. (0= no symptoms, 10 = worst symptom ever).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="5.66"/>
                    <measurement group_id="O2" value="4.7" spread="5.05"/>
                    <measurement group_id="O3" value="7.8" spread="8.66"/>
                    <measurement group_id="O4" value="6.8" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Efficacy of Side Effect Prevention Using the Acute Hangover Scale (Hangover Sensitive Subpopulation)</title>
        <description>Efficacy of pain medicine + antihistamine in reducing (as compared to placebo) symptoms associated with Veisalgia. The Acute Hangover Scale (AHS) will be used to evaluate side effects on the following morning post alcohol consumption. The scale includes 9 symptom assessments each ranging from 0-10. The total score can range from 0-90. (0= no symptoms, 10 = worst symptom ever).</description>
        <time_frame>24 hours</time_frame>
        <population>A subset of participants were analyzed post-hoc that were hangover sensitive when compared to placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Pain Medicine and Antihistamine</title>
            <description>JMI-001 (SJP-304 and SJP-223)
JMI-001 (SJP-304 and SJP-223)</description>
          </group>
          <group group_id="O2">
            <title>Pain Medicine</title>
            <description>SJP-304 and placebo
SJP-304
placebo</description>
          </group>
          <group group_id="O3">
            <title>Antihistamine</title>
            <description>SJP-223 and placebo
SJP-223
placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo + placebo, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Side Effect Prevention Using the Acute Hangover Scale (Hangover Sensitive Subpopulation)</title>
          <description>Efficacy of pain medicine + antihistamine in reducing (as compared to placebo) symptoms associated with Veisalgia. The Acute Hangover Scale (AHS) will be used to evaluate side effects on the following morning post alcohol consumption. The scale includes 9 symptom assessments each ranging from 0-10. The total score can range from 0-90. (0= no symptoms, 10 = worst symptom ever).</description>
          <population>A subset of participants were analyzed post-hoc that were hangover sensitive when compared to placebo.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="4.1"/>
                    <measurement group_id="O2" value="6" spread="6.5"/>
                    <measurement group_id="O3" value="9" spread="6.9"/>
                    <measurement group_id="O4" value="13.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pain Medicine and Antihistamine</title>
          <description>JMI-001 (SJP-304 and SJP-223)
JMI-001 (SJP-304 and SJP-223)</description>
        </group>
        <group group_id="E2">
          <title>Pain Medicine</title>
          <description>SJP-304 and placebo
SJP-304
placebo</description>
        </group>
        <group group_id="E3">
          <title>Antihistamine</title>
          <description>SJP-223 and placebo
SJP-223
placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo and placebo
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>epigastric pain</sub_title>
                <description>treatment not necessary</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Participants were not tested and excluded for hangover insensitivity, prior to being entered into the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Magdy Shenouda, MD</name_or_title>
      <organization>Clinilabs, Inc</organization>
      <phone>201-417-7765</phone>
      <email>Jackie@sen-jam.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

